thumbnail_dr-mahira

Dr. Mahira Zeeshan

Assistant Professor
PROFILE SUMMARY

Dr. Mahira Zeeshan has completed her Ph.D. degree in Pharmaceutics from “Quaid-i-Azam University, Islamabad, Pakistan”. She has been associated with academia and research for more than 5 years. Dr. Mahira published articles in reputable international journals (W category, Q1) with a cumulative research impact of >90. Her focus is on developing novel drug delivery strategies, exploring the world of nano pharmaceuticals with the preparation of several nanocarrier based drug targeting formulations, employing the latest techniques, introducing computational work in pharmaceutics, Quality by Design approach and design of experiments, in-dept formulation characterization using latest in vitro techniques, cell-based assays and development of in vivo animal models to determine the therapeutic efficacy of the nano formulations. Her thesis was declared best by foreign experts. Her academic life was remarkable with Gold Medals both in Pharm-D and MPhil Program for securing first position. She received academic scholarships including Riphah’s Musabiqat and Mumtaz merit, HEC-Indigenous and HEC-IRSIP fellowships (Germany) and also worked on the NRPU project. She is keen to proceed her research in pharmaceuticals development and drug delivery systems for various diseases. Her key achievements are development of novel drug delivery system for colon diseases.

QUALIFICATION
PhD Pharmaceutics Quaid-i-Azam University, Islamabad, Pakistan 2022
M.Phil Pharmaceutics Quaid-i-Azam University, Islamabad, Pakistan 2017
Pharm.D Pharmaceutical Sciences Riphah International University, Islamabad, Pakistan 2014
TEACHING EXPERIENCE
Assistant Professor Faculty of pharmacy, Capital university of Science and Technology, Islamabad, Pakistan Since -2023
Assistant Professor National Excellence Institute, Islamabad 2023 – 2023
MEMBERSHIP OF PROFESSIONAL BODIES
PPC Registered Pharmacist Punjab Pharmacy Council, Lahore
RESEARCH AREAS / INTERESTS
1. Formulation Design & Development
2. Pharmaceutical Nanotechnology
3. Sustained Drug Delivery System
4. Nano pharmaceutics
SR.JOURNAL PUBLICATIONSYEAR
1M. Zeeshan, H. Ali, S. Khan, S.A. Khan, B. Weigmann. “Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease.” International journal of pharmaceutics, 558, pp. 201-2142019
2M. Zeeshan, H. Ali, S. Khan, M. Mukhtar, M. I. Khan, M. Arshad. “Glycyrrhizic acid-loaded pH-sensitive poly-(lactic-co-glycolic acid) nanoparticles for the amelioration of inflammatory bowel disease.” Nanomedicine, Vol. 14, No. 15, pp. 1945-19692019
3Q. U. Ain, M. Zeeshan, S. Khan, H. Ali. “Biomimetic hydroxyapatite as potential polymeric nanocarrier for the treatment of rheumatoid arthritis.” Journal of Biomedical Materials Research Part A, Vol. 107, No. 12, pp. 2595-26002019
4M. Mukhtar, M. Zesshan, S. Khan, G. Shahnaz, S. A. Khan, H. S. Sarwar, R. A. Pasha, and H. Ali. “Fabrication and optimization of pH-sensitive mannose-anchored nano-vehicle as a promising approach for macrophage uptake.” Applied Nanoscience, Vol. 10, pp. 4013-40272020
5M. Mukhtar, E. Pallagi, I. Csóka, E. Benke, Á. Farkas, M. Zeeshan, K. Burián, D. Kókai, and R. Ambrus. “Aerodynamic properties and in silico deposition of isoniazid loaded chitosan/thiolated chitosan and hyaluronic acid hybrid nanoplex DPIs as a potential TB treatment.” International Journal of Biological Macromolecules, Vol. 165, pp. 3007-30192020
6E. Sana, M. Zeeshan, Q. Ain, A. U. Khan, I. Hussain, S. Khan, E. Lepeltier, and H. Ali. “Topical delivery of curcumin-loaded transfersomes gel ameliorated rheumatoid arthritis by inhibiting NF-κβ pathway.” Nanomedicine, Vol. 16, No. 10, pp. 819-8372021
7F. Sabir, M. Zeeshan, U. Laraib, M. Barani, A. Rahdar, M. Cucchiarini, and S. Pandey. “DNA based and stimuli-responsive smart nanocarrier for diagnosis and treatment of cancer: Applications and challenges.” Cancers, Vol. 13, No. 14 33962021
8M. Barani, M. Zeeshan, D. K. Neyestanaki, M. A. Farooq, A. Rahdar, N. K. Jha, S. Sargazi, P. K. Gupta, and V. K. Thakur. “Nanomaterials in the management of gram-negative bacterial infections.” Nanomaterials, Vol. 11, No. 10, pp. 25352021
9F. Sabir, M. Qindeel, M. Zeeshan, Q. U. Ain, A. Rahdar, M. Barani, E. González, and M. A. Aboudzadeh. “Onco-receptors targeting in lung cancer via application of surface-modified and hybrid nanoparticles: A cross-disciplinary review.” Processes, Vol. 9, No. 4, 6212021
10M. Zeeshan, A. Atiq, Q. U. Ain, J. Ali, S. Khan, and H. Ali. “Evaluating the mucoprotective effects of glycyrrhizic acid-loaded polymeric nanoparticles in a murine model of 5-fluorouracil-induced intestinal mucositis via suppression of inflammatory mediators and oxidative stress.” Inflammopharmacology, Vol. 29, pp. 1539-15532021
11M. Zeeshan, H. Ali, Q. U. Ain, M. Mukhtar, R. Gul, A. Sarwar, and S. Khan. “A holistic QBD approach to design galactose conjugated PLGA polymer and nanoparticles to catch macrophages during intestinal inflammation.” Materials Science and Engineering: C, Vol. 126, pp. 1121832021
12M. Barani, M. R. Hajinezhad, S. Sargazi, M. Zeeshan, A. Rahdar, S. Pandey, M. Khatami, and F. Zargari. “Simulation, in vitro, and in vivo cytotoxicity assessments of methotrexate-loaded pH-responsive nanocarriers.” Polymers, Vol. 13, No. 18, pp. 31532021
13M. Mukhtar, E. Fényes, C. Bartos, M. Zeeshan, and R. Ambrus. “Chitosan biopolymer, its derivatives and potential applications in nano-therapeutics: A comprehensive review.” European Polymer Journal, Vol. 160, pp. 1107672021
14K. Lechner, M. Zeeshan, M. Noack, H. Ali, M. F. Neurath, and B. Weigmann. “Small but powerful: will nanoparticles be the future state‐of‐the‐art therapy for IBD?.” Expert Opinion on Drug Delivery, Vol. 19, No. 3, pp. 235-2452022
15M. Zeeshan, Q. U. Ain, A. Sunny, F. Raza, M. Mohsin, S. Khan, B. Weigmann, and Hussain Ali. “QbD-based fabrication of transferrin-anchored nanocarriers for targeted drug delivery to macrophages and colon cells for mucosal inflammation healing.” Biomaterials Science2023

Other Members